Last reviewed · How we verify
SPARC1104 modified dose regimen II — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
SPARC1104 modified dose regimen II (SPARC1104 modified dose regimen II) — Sun Pharma Advanced Research Company Limited. SPARC1104 is a modified dose regimen of an undisclosed drug, but it is likely a small molecule targeting a specific molecular pathway.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SPARC1104 modified dose regimen II TARGET | SPARC1104 modified dose regimen II | Sun Pharma Advanced Research Company Limited | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SPARC1104 modified dose regimen II CI watch — RSS
- SPARC1104 modified dose regimen II CI watch — Atom
- SPARC1104 modified dose regimen II CI watch — JSON
- SPARC1104 modified dose regimen II alone — RSS
Cite this brief
Drug Landscape (2026). SPARC1104 modified dose regimen II — Competitive Intelligence Brief. https://druglandscape.com/ci/sparc1104-modified-dose-regimen-ii. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab